Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.

Next Previous
Trial Profile

Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPP 204106 (Primary)
  • Indications Bladder cancer; Breast cancer; Cancer; Lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Oct 2012 Status changed from recruiting to completed, according to an ImmuPharma media release.
  • 06 Dec 2010 New trial record
  • 19 Nov 2010 Brief preliminary results have been reported in an ImmuPharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top